Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Entravision Communication
EVC
$832M
| $5.43M | ﹤0.01% |
2,072,905
+216,200
| +12% | +$590K |
|
|
ERF
1802
DELISTED
Enerplus Corporation
ERF
| $5.42M | ﹤0.01% |
760,363
+380,606
| +100% | +$2.48M |
|
|
LNW
1803
DELISTED
Light & Wonder
LNW
| $5.42M | ﹤0.01% |
202,300
-275,300
| -58% | -$7.09M |
|
|
GAU
1804
Galiano Gold
GAU
$547M
| $5.4M | ﹤0.01% |
5,683,546
+112,734
| +2% | +$100K |
|
1805
Stantec
STN
$8.41B
| $5.4M | ﹤0.01% |
190,730
+49,130
| +35% | +$1.21M |
|
|
ATRS
1806
DELISTED
Antares Pharma, Inc.
ATRS
| $5.38M | ﹤0.01% |
1,144,707
+1,016,579
| +793% | +$4.16M |
|
1807
Gran Tierra Energy
GTE
$325M
| $5.37M | ﹤0.01% |
416,159
-68,861
| -14% | -$751K |
|
1808
AeroVironment
AVAV
$9.76B
| $5.36M | ﹤0.01% |
86,836
-192,100
| -69% | -$11.5M |
|
1809
United-Guardian
UG
$32.8M
| $5.36M | ﹤0.01% |
272,800
+3,500
| +1% | +$67.2K |
|
|
CCRN
1810
DELISTED
Cross Country Healthcare
CCRN
| $5.33M | ﹤0.01% |
458,930
+226,930
| +98% | +$2.56M |
|
|
XHR
1811
Xenia Hotels & Resorts
XHR
$1.77B
| $5.33M | ﹤0.01% |
246,700
-81,860
| -25% | -$1.73M |
|
1812
Minerva Neurosciences
NERV
$219M
| $5.33M | ﹤0.01% |
93,625
+4,100
| +5% | +$181K |
|
|
CBPO
1813
DELISTED
China Biologic Products Holdings, Inc.
CBPO
| $5.32M | ﹤0.01% |
45,700
+30,700
| +205% | +$3.56M |
|
1814
Luxfer Holdings
LXFR
$457M
| $5.32M | ﹤0.01% |
287,200
-270,500
| -49% | -$4.66M |
|
1815
American States Water
AWR
$3.53B
| $5.29M | ﹤0.01% |
61,063
-74,277
| -55% | -$6.58M |
|
1816
Diamondrock Hospitality Co
DRH
$2.53B
| $5.28M | ﹤0.01% |
476,869
-602,815
| -56% | -$6.22M |
|
|
FLNA
1817
Filana Therapeutics
FLNA
$44.1M
| $5.28M | ﹤0.01% |
1,015,759
+163,801
| +19% | +$283K |
|
1818
Apyx Medical
APYX
$128M
| $5.27M | ﹤0.01% |
622,895
-29,905
| -5% | -$216K |
|
1819
Aclaris Therapeutics
ACRS
$851M
| $5.26M | ﹤0.01% |
2,782,297
+813,581
| +41% | +$1.35M |
|
1820
John B. Sanfilippo & Son
JBSS
$1.01B
| $5.26M | ﹤0.01% |
57,600
+41,300
| +253% | +$4.01M |
|
1821
Axsome Therapeutics
AXSM
$11.2B
| $5.25M | ﹤0.01% |
+50,770
| New | +$2.05M |
|
|
TACO
1822
DELISTED
Del Taco Restaurants, Inc. Common Stock
TACO
| $5.24M | ﹤0.01% |
663,162
-177,838
| -21% | -$1.44M |
|
1823
Invesco Emerging Markets Sovereign Debt ETF
PCY
$1.39B
| $5.23M | ﹤0.01% |
176,900
+63,344
| +56% | +$1.84M |
|
1824
Hovnanian Enterprises
HOV
$785M
| $5.22M | ﹤0.01% |
249,915
+118,500
| +90% | +$2.8M |
|
1825
Tapestry
TPR
$26.1B
| $5.21M | ﹤0.01% |
+193,000
| New | +$5.03M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.